CL 275838: structure given in first source; a potential memory-enhancing agent (cognition enhancer) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 163983 |
| SCHEMBL ID | 194368 |
| MeSH ID | M0201974 |
| Synonym |
|---|
| 115931-65-2 |
| cl 275838 |
| pyrazolo(1,5-a)pyrimidine-3-carbonitrile, 4,5-dihydro-4-((4-(phenylmethyl)-1-piperazinyl)acetyl)-7-(3-(trifluoromethyl)phenyl)- |
| 4-[2-(4-benzylpiperazin-1-yl)acetyl]-7-[3-(trifluoromethyl)phenyl]-5h-pyrazolo[1,5-a]pyrimidine-3-carbonitrile |
| cl 275,838 |
| 4,5-dihydro-4-((4-(phenylmethyl)-1-piperazinyl)acetyl)-7-(3-(trifluoromethyl)phenyl)pyrazolo(1,5-a)pyrimidine-3-carbonitrile dihydrochloride |
| pyrazolo (1,5-a)pyrimidine-3-carbonitrile, 4,5-dihydro-4-((4-(phenylmethyl)-1-piperazinyl)acetyl)-7-(3-(trifluoromethyl)phenyl)- |
| SCHEMBL194368 |
| DTXSID10151234 |
| CS-6722 |
| HY-19146 |
| cl-275838 |
| kvrvfybzhkpbdb-uhfffaoysa-n |
| pyrazolo[1,5-a]pyrimidine-3-carbonitrile, 4,5-dihydro-4-[2-[4-(phenylmethyl)-1-piperazinyl]acetyl]-7-[3-(trifluoromethyl)phenyl]- |
| AKOS040741556 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " At steady state, mean Cmax and AUC of the parent compound and its two metabolites were dose related." | ( Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteers. Caccia, S; Confalonieri, S; Guido, M; Guiso, G; Lucca, U; Parma, E; Spagnoli, A; Tettamanti, M; Tiraboschi, P, 1994) | 0.29 |
| " In young male volunteers both Cmax and area under the curve (AUC) increased proportionally with dose from 10 to 100 mg." | ( Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers. Caccia, S; Confalonieri, S; Guido, M; Guiso, G; Lucca, U; Parma, E; Spagnoli, A; Tettamanti, M; Tiraboschi, P, 1993) | 0.29 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (14.29%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||